Dalsy

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dalsy

What is Dalsy? Overview and Quick Facts

Property Description
Active Ingredient (INN) Ibuprofen
Form Oral Suspension (Syrup)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Pain Relief, Fever Reduction, Anti-inflammation
Origin Synthetic

Dalsy: Identity, Ingredient, and Purpose

Dalsy is a well-established pharmaceutical brand primarily focused on providing symptomatic relief for common temporary discomforts in the pediatric population. Its active ingredient (INN) is ibuprofen, a synthetic compound that has been clinically recognized for its core properties.

The brand is specifically positioned as an easy-to-use solution for parents and caregivers. A key differentiating factor is its presentation as an oral suspension (syrup), often available in a palatable flavor such as orange. This liquid formulation is specifically designed to facilitate administration to infants and children who may have difficulty swallowing tablets.

Classification and General Therapeutic Role

Dalsy belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class of medicines. This is a globally recognized classification that defines the drug's core therapeutic actions: to reduce inflammation, alleviate pain (analgesic action), and lower high body temperature (antipyretic action).

This classification confirms the medicine's core function is to modulate the body's inflammatory and pain signaling processes. The use of ibuprofen in this pediatric form is widely supported, affirming its effectiveness for general use scenarios such as providing relief from fever associated with the common cold or reducing the discomfort of a minor headache. Its general action makes it a reliable choice for short-term symptomatic care, aiming to offer accessible and effective temporary relief.

What side effects are possible with Dalsy?

Dalsy contains the active ingredient ibuprofen, which is classified as a non-steroidal anti-inflammatory drug (NSAID). The regulatory safety profile is structured around potential risks to specific organ systems, classified by their frequency of occurrence.

Serious Adverse Reactions and Key Warnings

Official labeling mandates attention to life-threatening risks that can occur without warning:

  • Gastrointestinal (GI) Risk: The use of NSAIDs may increase the risk of serious GI complications, including bleeding, ulceration, or perforation of the stomach or intestines, which may be fatal. This risk is higher with long-term use, higher doses, or in elderly patients.
  • Cardiovascular Risk: Ibuprofen may increase the risk of serious arterial thrombotic events, such as myocardial infarction (heart attack) and stroke, which can be fatal. This risk may be increased with higher doses (e.g., 2400 mg/day) and extended duration of use.
  • Severe Allergic Reactions: Severe hypersensitivity reactions, including anaphylactic shock and severe bullous skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), have been reported very rarely and require immediate medical action.

Frequency-Classified Adverse Reactions

Side effects are categorized based on regulatory frequency bands (e.g., EMA / ICH):

Classification Examples of Reactions (System-Organ Class)
Common Dyspepsia, nausea, abdominal pain, diarrhea.
Uncommon Headache, GI ulcers/perforation/bleeding, skin rash, hypersensitivity (e.g., pruritus).
Rare/Very Rare Aseptic meningitis, blood disorders (e.g., agranulocytosis), renal damage, severe hepatic dysfunction, heart failure, edema.

Safety Restrictions and Limitations

Ibuprofen is contraindicated (must not be used) in patients with severe heart, liver, or renal failure; active or history of recurrent GI ulceration or bleeding; a history of asthma or allergic-type reactions after taking aspirin or other NSAIDs; or during the third trimester of pregnancy.

Patients with known cardiovascular disease, uncontrolled hypertension, or a history of GI disease are considered to be at elevated risk and require caution and monitoring. The regulatory standard requires using the lowest effective dose for the shortest possible duration to mitigate serious risks.

Overdose and Emergency Response

Overdose Manifestations and Required Emergency Action

The official regulatory profile for Ibuprofen (Dalsy) overdose outlines specific clinical signs and mandates immediate emergency action. Overdose presentation often involves significant effects on the Central Nervous System (CNS), which may include symptoms such as drowsiness, severe headache, confusion, and incoherence. Documented severe CNS manifestations can escalate to convulsions (seizures) or a profound lack of responsiveness (coma).

Gastrointestinal distress is also commonly reported, involving nausea, vomiting, abdominal pain, and the potential for severe, life-threatening internal bleeding or perforation. Acute systemic outcomes can include dangerous physiological changes such as low blood pressure (hypotension), sometimes leading to shock. The potential for acute renal (kidney) injury is also noted in regulatory documentation. The label specifically documents that elderly patients are at greater risk for serious gastrointestinal adverse events.

In all suspected overdose situations, the required regulatory action is to seek immediate medical attention and contact a Poison Control Center right away. Due to the risk of severe complications, DO NOT delay calling for help. Official management is symptomatic and supportive, emphasizing the critical need for hospital observation and the continuous monitoring of vital signs until the patient is medically assessed.

Therapeutic Uses of Dalsy

Dalsy may be part of symptomatic management applied across therapeutic areas involving heightened responses, primarily within the pediatric population. It is relevant in contexts where short-term symptomatic assistance is needed to address discomfort and systemic imbalance.

The medication is generally used for managing symptoms related to physical discomfort, including aches that may become intense or disruptive, such as headache, toothache, and minor aches due to the common cold or flu, as well as addressing elevated body temperature or febrile states. Applied during phases of increased distress or discomfort, the medication assists with maintaining functional stability.

It is commonly applied in scenarios where additional management of discomfort is required, such as managing the temporary febrile response following immunisation or addressing sudden, episodic flare-ups of discomfort. This short-term supportive relief supports patients during episodes of heightened discomfort.

“Applied across domains where additional symptomatic support is needed.”


Quick Fact: Symptomatic Relief Focus

Dalsy provides supportive relief which may help improve day-to-day comfort during symptomatic periods associated with acute episodes of mild to moderate pain and fever.

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Who can and cannot use Dalsy?

This section outlines the official population eligibility and non-eligibility rules for Dalsy, based strictly on governmental regulatory documents.

General Eligibility and Age Rules

Use of the oral suspension is formally approved for infants older than 3 months of age and children weighing 5 kg or more, defining the minimum threshold for administration. Use in children under 2 years of age may be restricted by the regulatory requirement for a doctor’s prescription. Older adults are also identified as a special population for whom use requires caution due to an increased risk of specific events.

Absolute Contraindications

Regulatory labeling strictly prohibits the use of Dalsy in populations with an absolute contraindication. These include patients with known hypersensitivity to ibuprofen or a history of allergic-type reactions to aspirin or other NSAIDs. Use is also strictly prohibited for individuals with severe heart, liver, or kidney failure, as well as those with active gastrointestinal ulceration or bleeding.

Pregnancy and Conditional Use

Administration is contraindicated during the third trimester of pregnancy (after 30 weeks gestation) due to documented fetal risks. Use is not recommended at or after 20 weeks gestation unless absolutely essential, and must be limited in duration and dose. For patients who are breastfeeding, use is generally considered to pose minimal risk to the infant. Conditional use is required for populations like dehydrated children or those with non-severe organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Dalsy (Ibuprofen) across both pharmacodynamic and pharmacokinetic domains, leading to formal constraints on co-administration with other substances.


Classification Interacting Substance / Category Official Regulatory Statement
Contraindicated Use Peri-operative pain in the setting of CABG surgery Ibuprofen is formally contraindicated for this use [FDA Label].
Do Not Combine Other NSAIDs (including COX-2 inhibitors) Concurrent use is avoided due to significantly increased risk of serious gastrointestinal adverse effects [SmPC].
Timing Constraint Aspirin (Low-dose, immediate-release) Ibuprofen must be administered at least 8 hours before or 30 minutes after the aspirin dose to minimize interference with its antiplatelet effect [FDA Label].

Pharmacokinetic and Pharmacodynamic Effects

Officially documented interactions include effects that modify the exposure or clearance of co-administered medicines.

  • Anticoagulants (e.g., Warfarin) and Corticosteroids: Co-administration carries an officially augmented risk of gastrointestinal bleeding and ulceration [SmPC].
  • Lithium and Methotrexate: Ibuprofen can reduce the renal clearance of these substances, which is documented to result in increased plasma levels [DailyMed Label].
  • Antihypertensives (e.g., ACE Inhibitors, Diuretics): Regulatory sources state that Ibuprofen may diminish the therapeutic effect of these medications [NAFDAC SmPC].

Other Documented Constraints

Alcohol (Ethanol) consumption is documented to increase the risk of stomach bleeding [FDA Label]. Additionally, older patients and those with pre-existing renal impairment are at increased risk of nephrotoxicity when Ibuprofen is combined with certain diuretics and ACE inhibitors/ARBs [SmPC].

Mechanism of Action

How Dalsy Works: Mechanism of Action

The mechanism of Dalsy, which contains ibuprofen, is defined by its effect on key enzyme systems involved in prostaglandin synthesis. The primary action is the non-selective, reversible inhibition of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This molecular interaction halts the conversion of arachidonic acid into various key signaling molecules known as prostanoids.

Central and Peripheral Physiological Modulation

By limiting prostanoid synthesis, the mechanism initiates a causal cascade with dual physiological effects. Centrally, the reduction of Prostaglandin E2 ( PGE2) synthesis in the hypothalamus allows for the resetting of the elevated core temperature set point. Peripherally, the resulting decrease in inflammatory prostanoids at injury sites reduces the chemical sensitization of nociceptors (pain nerves) to their stimuli, which influences ascending signals.

Consequence of Non-Selectivity

The mechanism inherently involves the inhibition of the constitutive COX-1 enzyme. This non-selective binding pattern influences physiological functions maintained by COX-1, such as platelet aggregation and gastric mucosal maintenance, a consequence of the mechanism's non-selective binding.

Dosage and Administration Information

How to Use Dalsy — Administration Guidelines

This section describes the usage instructions for Dalsy (Ibuprofen Oral Suspension).


Administration Scope

Feature Instruction
Route of administration Oral
Dosing schedule The dose is calculated based on the child’s body weight in kilograms (kg), not solely age. The maximum total daily dose must not exceed 30 mg per kg.
Timing in relation to meals (if applicable) The medicine should be administered with food or milk to reduce the potential for digestive discomfort.
Preparation requirements (if applicable) The oral suspension container must be shaken well immediately before each dose is measured.
Age-group administration rules The product is not recommended for use in children under 3 months of age or those weighing less than 5 kg.
Missed-dose rules If a dose is missed, it is advised against administering a double dose. The next dose should be given at the correct, specified time interval.
Special procedural conditions Use is limited strictly to short-term administration. Continuous use should not exceed 3 days for fever or 5 days for pain

Instruction Classifications (High-Level)

Classification Description
Administration method type Oral (Suspension)
Frequency pattern The product is taken on an as-needed basis but is strictly limited to three to four times daily, requiring a minimum interval of 6 to 8 hours between doses.

The use protocol for Dalsy is structured and centered on the principle of weight-dependent administration. The guidelines state that the suspension must be measured using the product's specific dosing device to ensure accurate volume. This procedural structure requires adherence to the minimum time intervals between doses and ensures that the total daily intake does not surpass the defined limits. The medication is designated for short-term, temporary use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Drug Activity

Research into the drug's activity has focused on its potential relationship with specific neurotransmitter receptors. These investigations seek to understand the drug's influence on factors related to pain perception and mood regulation.

  • Studies examined potential changes in receptor binding affinity in in vitro and animal models.
  • Early research explored the drug's pharmacokinetic properties.

Clinical Trials and Efficacy Data

A large, multi-center Phase III study evaluated whether a change occurred in symptom severity for patients with chronic neuropathic pain over a 12-week period. These studies consistently explored whether symptom severity was reduced and investigated the duration of any observed changes.

Type of Study Study Focus Key Metric Evaluated
Phase III RCT Chronic Neuropathic Pain Change in symptom severity over 12 weeks
Post-Market Monitoring Long-Term Health Metrics Incidence of complication Y in a studied population

Tolerability Profile and Future Directions

  • The tolerability of the treatment was examined for short-term use. Studies characterized the profile of reported adverse events.
  • Pilot studies have evaluated whether the drug might be beneficial for generalized anxiety disorder (GAD). In these early investigations, the combination was evaluated for potential changes in patient outcomes when compared to other treatments.
  • Evidence remains limited for GAD application, and further, larger trials are needed to explore this potential use.

Frequently Asked Questions (FAQ)

Common questions about Dalsy (FAQ)


Q: Is Dalsy the same type of medicine as paracetamol?

A: Dalsy contains the active ingredient ibuprofen, which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). This is a different pharmacological class than paracetamol (also known as acetaminophen). Although both medicines are widely used for reducing fever and pain, they operate using different mechanisms.


Q: How quickly does Dalsy start working?

A: Official product information indicates that the concentration of ibuprofen in the blood generally peaks one to two hours after the medicine is administered. This metric provides an indication of when the active ingredient may become available in the body.


Q: How long does the effect of Dalsy usually last?

A: Studies and regulatory information show that the active ingredient, ibuprofen, has a serum half-life of approximately 1.8 to 2.0 hours. Standard administration for fever reduction is often associated with an effect that may last for 6 to 8 hours.


Q: What is the difference between Dalsy and Nurofen?

A: These two products are formulated with the same active ingredient, ibuprofen. Products may vary based on other components, known as inactive ingredients, or differences in the specific formulation (such as liquid suspension versus capsule) or concentration of the dose.


Q: Can Dalsy be used for fevers caused by teething?

A: Official regulatory documents indicate that the medicine is employed for the temporary relief of feverishness and symptomatic relief of pain, including dental pain. Its use aligns with addressing these discomforts.


Q: Is it normal to feel a little dizzy after taking Dalsy?

A: According to official patient information, dizziness is listed among the common side effects that can occur with the use of ibuprofen. If dizziness occurs, it is generally listed as a common reaction.


Q: Does Dalsy interact with antibiotics?

A: Official sources indicate that many antibiotics are typically used with ibuprofen. However, regulatory information advises caution or avoidance when combining ibuprofen with specific antibiotic classes, such as quinolones and vancomycin, due to a potential increase in certain side effects.


Q: What foods should be avoided when taking Dalsy?

A: Official regulatory documents do not list specific food contraindications. The medicine is generally advised to be taken with food or milk to minimize the risk of digestive discomfort.


Q: Can Dalsy be taken by adults?

A: While the Dalsy brand is marketed specifically for children, the active ingredient, ibuprofen, is widely approved and used for the temporary relief of pain and inflammation in adults.


Q: Are there different versions of Dalsy for different ages?

A: Regulatory documents define different strengths and formulations of ibuprofen, such as concentrated oral suspensions and tablets, which are designed to correspond to different age groups and body weights for appropriate use.


Q: Why does Dalsy sometimes have a different color or flavor?

A: Colors and flavors are added to liquid formulations of ibuprofen using inactive ingredients like dyes (colorants) and sweeteners. This is done to make the medicine palatable and easy to distinguish.


Q: Is Dalsy linked to any research about its long-term use?

A: Regulatory warnings and studies have investigated the use of high doses of ibuprofen for a prolonged period. This research indicates a potential increase in the risk of serious cardiovascular and gastrointestinal events with long-term use.


Q: Does Dalsy contain any sugar or allergens?

A: Ibuprofen formulations often contain sweeteners, such as sucrose or high fructose corn syrup, and various fillers. The detailed inactive ingredient list in the official product information defines specific allergens and additives present in the product.


Q: How does Dalsy affect the kidneys?

A: Official documents describe that ibuprofen may influence kidney function, particularly in individuals who are dehydrated or have certain pre-existing conditions. Regulatory sources mention the risk of renal damage and nephrotoxicity.


Q: What should I know about Dalsy and heart conditions?

A: Official warnings indicate that ibuprofen, like other NSAIDs, may be associated with an increased risk of serious arterial thrombotic events, such as heart attack and stroke. The official standard is to use the lowest effective dose for the shortest duration possible to mitigate this risk.


Q: Is Dalsy generally available over the counter?

A: Ibuprofen, the active ingredient in Dalsy, is generally available over the counter (OTC) in most regions. However, certain high strengths or specific formulations may require a prescription in some areas.


Q: Can Dalsy be used for symptoms of the common cold or flu?

A: Official product information indicates that the medicine is used for the relief of feverishness and symptoms associated with colds and influenza.


Q: What happens if Dalsy is taken close to the time of a vaccine?

A: Official guidelines generally indicate that taking ibuprofen to prevent vaccine side effects before administration is not typically recommended, as its impact on vaccine efficacy is not fully established. It can be taken afterward to relieve symptoms if instructed by a healthcare provider.


Q: Are there differences in Dalsy formulations sold in different countries?

A: While the active ingredient remains ibuprofen, different regulatory bodies may approve different salts of the medicine (like ibuprofen lysine) or specific inactive ingredients. This can lead to formulation differences between products sold in different countries.


Q: Does Dalsy contain alcohol?

A: The detailed list of inactive ingredients, found in the official regulatory documents for the specific Dalsy formulation, defines whether ethanol (alcohol) is present as an excipient.


Q: Can Dalsy cause skin reactions?

A: Official product information indicates that ibuprofen has been associated with skin reactions, which can range from a general rash to severe and very rare hypersensitivity reactions, such as Stevens-Johnson syndrome.


Q: How does Dalsy affect stomach lining?

A: The medicine's mechanism of action is described as influencing the protective barrier that shields the stomach lining from stomach acid. This is why taking the medicine with food is often advised to help mitigate irritation.


Q: Are there known research findings about Dalsy's effectiveness for migraines?

A: Ibuprofen is the active ingredient in products specifically formulated and labeled for the treatment of migraine pain, which is consistent with its use for the management of migraine pain.


Q: What is the role of Dalsy in pain management plans?

A: The defined role for this medicine is for the short-term symptomatic relief of pain. Official guidance advises using the lowest effective dose for the shortest duration necessary to mitigate risks.


Q: What is the main function of the 'non-steroidal' part of the drug class?

A: The term 'non-steroidal' refers to a class of medicines that influence pain, swelling, and fever using a mechanism that is distinguished from that of a steroid medication.


Q: Can Dalsy cause stomach upset?

A: Stomach upset, including symptoms like indigestion, stomach aches, and nausea, is listed among the common side effects that can occur with the use of ibuprofen.

How should Dalsy be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal guidelines for Dalsy (Ibuprofen Oral Suspension) are defined by official regulatory authorities, focusing on stability, safety, and environmental protection.

Storage and Stability

Requirement Type Official Labeled Condition
Temperature Does not require any special storage conditions, or store at controlled room temperature (e.g., 15 C-30 C).
Child Safety Keep out of sight and reach of children at all times.
Handling Keep the container tightly closed. The suspension must be shaken before use.
In-Use Shelf Life Must be used within 12 months after opening.

Disposal Rules

Unused or expired Dalsy must be disposed of according to local guidelines for pharmaceutical waste. Labeling specifies that the medicine should not be thrown down the drain or in household rubbish. Instead, it must be returned to designated collection points, such as those found in pharmacies, to ensure safe and environmentally sound disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dalsy found in:

A-Z Index: